<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2021000400020</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x20210004000020</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Rituximab en combinación con agentes "bypass" hemostáticos para hemofilia adquirida con inhibidor, a propósito de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Rituximab in combination with hemostatic "bypass" agents for hemophilia acquired with an inhibitor, in the event of a case]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tejedor-Tejada]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jurado-Herrera]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Núñez]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Torrecárdenas Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Almería ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>31</volume>
<numero>4</numero>
<fpage>433</fpage>
<lpage>434</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2021000400020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2021000400020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2021000400020&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La hemofilia adquirida es un trastorno hemorrágico producido por anticuerpos del propio organismo que actúan frente al factor VIII. Posee una incidencia estimada 1-1,5 casos/millón/año, con predominio en sujetos de edad avanzada. Es considerada una enfermedad rara pero su impacto puede verse infraestimado por la falta de registros adecuados, la falta de conocimiento por el facultativo y su complejidad para diagnosticarla. No hay establecido un protocolo fijo en el manejo de la patología, por ello la mayoría de las recomendaciones se basan en las opiniones de expertos en el tratamiento de otras coagulopatías.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY Acquired hemophilia is a bleeding disorder caused by the body's own antibodies to factor VIII. It has an estimated incidence of 1-1.5 cases/million/year, with a predominance of elderly subjects. It is considered a rare disease but its impact may be underestimated due to the lack of adequate records, the lack of knowledge by the specialists and its complexity in diagnosing it. There is no fixed protocol in the management of the pathology, so the majority of recommendations are based on the opinions of experts in the treatment of other coagulopathies.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hemofilia A]]></kwd>
<kwd lng="es"><![CDATA[sangre]]></kwd>
<kwd lng="es"><![CDATA[rituximab]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos]]></kwd>
<kwd lng="es"><![CDATA[factores inmunológicos]]></kwd>
<kwd lng="es"><![CDATA[uso terapéutico]]></kwd>
<kwd lng="es"><![CDATA[factor VIII]]></kwd>
<kwd lng="es"><![CDATA[antagonistas e inhibidores]]></kwd>
<kwd lng="en"><![CDATA[Hemophilia A]]></kwd>
<kwd lng="en"><![CDATA[blood]]></kwd>
<kwd lng="en"><![CDATA[rituximab]]></kwd>
<kwd lng="en"><![CDATA[antibodies]]></kwd>
<kwd lng="en"><![CDATA[immunologic factors]]></kwd>
<kwd lng="en"><![CDATA[therapeutic use]]></kwd>
<kwd lng="en"><![CDATA[factor VIII]]></kwd>
<kwd lng="en"><![CDATA[antagonists &amp; inhibitors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franchini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lippi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acquired factor VIII inhibitors]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2008</year>
<volume>112</volume>
<page-range>250-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Livnat]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Budnik]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Levy-Mendelovich]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Avishai]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Misgav]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barg]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors]]></article-title>
<source><![CDATA[Blood Cells Mol Dis]]></source>
<year>2017</year>
<numero>66</numero>
<issue>66</issue>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[P. W]]></given-names>
</name>
<name>
<surname><![CDATA[Mathias]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hanley]]></surname>
<given-names><![CDATA[Jj]]></given-names>
</name>
<name>
<surname><![CDATA[Keeling]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Keenan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Laffan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rituximab and immune tolerance in severe hemophilia A:a consecutive national cohort]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2009</year>
<volume>7</volume>
<page-range>787-94</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baudo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Huth-Kuhne]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of bleeding in acquired hemophilia A: Results of the European Acquired Haemophilia (EACH2) registry]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>120</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-46</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franchini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Castaman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Coppola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santoro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zanon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Di Minno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management]]></article-title>
<source><![CDATA[Blood Transfus]]></source>
<year>2015</year>
<volume>13</volume>
<page-range>498-513</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
